tiprankstipranks
Trending News
More News >
Compumedics Limited (AU:CMP)
ASX:CMP
Australian Market
Advertisement

Compumedics Limited (CMP) AI Stock Analysis

Compare
4 Followers

Top Page

AU:CMP

Compumedics Limited

(Sydney:CMP)

Rating:60Neutral
Price Target:
AU$0.50
▲(66.67%Upside)
The overall stock score of 60 is driven by positive technical momentum and revenue growth, but is tempered by significant profitability challenges and negative valuation metrics. The stock's upward trend is promising, but caution is warranted due to the stock's overvaluation and lack of profitability.

Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)

Compumedics Limited Business Overview & Revenue Model

Company DescriptionCompumedics Limited (CMP) is a medical technology company that specializes in the development, manufacturing, and commercialization of diagnostic technology for sleep, neurological, and ultrasonic blood flow monitoring applications. With a focus on innovative health solutions, Compumedics serves hospitals, clinics, and research institutions across the globe, providing advanced monitoring systems and software to facilitate better patient outcomes in areas such as sleep disorders and neurological diseases.
How the Company Makes MoneyCompumedics Limited generates revenue primarily through the sale of its diagnostic equipment and related software solutions. The company offers a range of products including sleep diagnostic systems, neurological monitoring devices, and Doppler blood flow systems. These products are sold to healthcare facilities, research institutions, and distributors worldwide. Additionally, Compumedics may derive income from service contracts, equipment maintenance, and software upgrades, which provide ongoing support and enhancements to their product offerings. Strategic partnerships and collaborations with medical and research organizations also play a role in expanding the company's market reach and driving revenue growth.

Compumedics Limited Financial Statement Overview

Summary
Compumedics Limited shows positive revenue growth and stable gross profit margins, indicating recovery potential. However, negative net income, EBIT, and free cash flow present significant profitability challenges. The company's moderate leverage requires improved profitability for financial stability.
Income Statement
65
Positive
Compumedics Limited has shown a positive revenue growth rate of 17.23% from 2023 to 2024, indicating a recovery trend. However, the company continues to experience negative net income and EBIT, resulting in negative net and EBIT margins. Gross profit margins have remained relatively stable, suggesting efficient cost management at the gross level but challenges in operational efficiency.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio has increased slightly, indicating a moderate level of leverage. The equity ratio stands at 45.11%, which reflects a balanced capital structure but a decrease from previous years. Return on equity remains negative due to net losses, highlighting profitability challenges.
Cash Flow
55
Neutral
Compumedics Limited's free cash flow has improved from 2023 to 2024 but remains negative. The operating cash flow to net income ratio is favorable, suggesting that cash flow generation relative to net income is strong. However, the overall negative free cash flow indicates ongoing challenges in generating sufficient cash from operations.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue50.26M42.41M37.76M35.74M35.07M
Gross Profit26.07M21.59M19.32M19.16M18.01M
EBITDA2.79M-5.05M3.31M2.56M-5.42M
Net Income-338.00K-6.12M1.36M998.00K-5.84M
Balance Sheet
Total Assets40.36M41.18M41.71M38.55M35.53M
Cash, Cash Equivalents and Short-Term Investments1.89M3.80M7.29M6.77M6.41M
Total Debt8.58M9.47M6.55M5.82M4.80M
Total Liabilities22.15M22.89M18.12M16.39M13.73M
Stockholders Equity18.21M18.29M23.59M22.16M21.79M
Cash Flow
Free Cash Flow-986.00K-4.36M302.00K-230.00K1.15M
Operating Cash Flow2.00M49.00K3.29M1.32M5.38M
Investing Cash Flow-2.99M-4.41M-2.98M-1.55M-4.23M
Financing Cash Flow-1.49M-1.00M1.61M-179.00K448.00K

Compumedics Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.30
Price Trends
50DMA
0.28
Positive
100DMA
0.28
Positive
200DMA
0.28
Positive
Market Momentum
MACD
<0.01
Negative
RSI
64.19
Neutral
STOCH
72.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.28, and above the 200-day MA of 0.28, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 64.19 is Neutral, neither overbought nor oversold. The STOCH value of 72.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CMP.

Compumedics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
AU$56.70M-8.08%-5.62%-225.71%
58
Neutral
$149.11M-15.86%12.93%62.47%
57
Neutral
AU$107.46M-51.08%10.22%-2.94%
51
Neutral
AU$147.94M-58.61%-74.88%
50
Neutral
AU$2.63B2.90-57.47%2.40%36.37%14.48%
48
Neutral
AU$11.78M-98.08%-7.44%30.34%
45
Neutral
AU$120.03M-35.20%4.68%-155.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CMP
Compumedics Limited
0.30
0.00
0.00%
AU:IPD
Impedimed Limited
0.05
-0.01
-19.70%
AU:SOM
Somnomed Limited
0.69
0.32
85.14%
AU:CYC
Cyclopharm Limited
1.08
-0.52
-32.50%
AU:EMV
EMvision Medical Devices Ltd.
1.80
-0.19
-9.55%
AU:CBL
Control Bionics Ltd.
0.04
-0.01
-20.00%

Compumedics Limited Corporate Events

Compumedics Limited Reports Record Sales and Strategic Growth in FY25
Jul 14, 2025

Compumedics Limited has announced a record-breaking fiscal year 2025, characterized by a 22% increase in sales orders and a return to profitability. The company’s strategic focus on the US market and SaaS platforms has driven significant growth, with US sales orders up by 115% and SaaS orders increasing by 49%. Looking ahead, Compumedics aims to scale its business model with new product launches and recurring revenue streams, projecting a revenue of at least $70 million and an EBITDA of approximately $9 million for FY26. The launch of the disposable Somfit in the US and the expansion of the MEG systems into the pediatric market are expected to further enhance the company’s market position and revenue potential.

Compumedics Adjusts FY25 Financial Guidance and Confirms FY26 Outlook
May 21, 2025

Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.

Compumedics Secures $1M Somfit Contract with Leading US CRO
May 21, 2025

Compumedics Limited has secured a significant contract worth $1 million for its Somfit device with a leading pharmaceutical Contract Research Organisation in the USA. This sale is part of Compumedics’ strategy to expand beyond the home sleep testing market into pharmaceutical clinical trials, leveraging Somfit’s ability to directly track brain signals for accurate sleep architecture analysis. The contract highlights the company’s strong growth in the USA, with sales orders reaching $12 million this year, a 130% increase from the previous year. Compumedics anticipates continued growth, projecting sales orders over $60 million for FY25, although revenue and EBITDA expectations have been adjusted due to the rapid business expansion.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025